Diquafosol tetrasodium: a novel dry eye therapy.
The ophthalmic formulation of diquafosol tetrasodium (INS365), a P2Y2 receptor agonist, is targeted to treat dry eye disease through rehydration of the ocular surface. Existing pharmacological therapies for dry eye disease are limited, therefore, approval of this medication is anticipated. This review summarises key findings during development and in clinical trials including clinical effectiveness and safety. The relevance of P2Y2 receptor technology to dry eye disease and the disease process is discussed.
Nichols
Kelly K
KK
The Ohio State University, College of Optometry, Columbus, OH, USA.
Yerxa
Ben
B
Kellerman
Donald J
DJ
D001682:Biological Availability; D002986:Clinical Trials as Topic; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D009883:Ophthalmic Solutions / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011122:Polyphosphates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D058910:Purinergic P2 Receptor Agonists; D016896:Treatment Outcome; D014500:Uracil Nucleotides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D009883:Ophthalmic Solutions; D011122:Polyphosphates; D058910:Purinergic P2 Receptor Agonists; D014500:Uracil Nucleotides; C403315:diquafosol